MetaCap

Kyverna Therapeutics (KYTX) vs SL Science (SLBT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kyverna Therapeutics (KYTX) has outperformed SL Science (SLBT) over the past year, losing 39.9% versus a loss of 94.8%. SL Science is the larger company by market cap ($308.4 million vs $269.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KYTX-39.92%SLBT-94.76%
+66%-18%-102%
Nov 21, 20251 yearNov 20, 2026
KYTX+42.00%SLBT-94.51%
+247%+68%-111%
Feb 3, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KYTX versus SLBT key metrics
MetricKYTXSLBT
Share price$4.26$0.55
Market cap$269.33M$308.42M
1-day change-2.52%-3.36%
YTD return-54.68%-94.78%
1-year return-39.92%-94.76%
EPS (TTM)$-2.75$0.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-161.31M—
52-week high$13.67$14.50
52-week low$4.18$0.51
Distance from 52-week high-68.84%-96.21%
Analyst consensusstrong_buy—
Avg. price target upside+613.62%—
Average volume867.28K67.66K
Shares outstanding63.22M560.76M
Employees17214
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KYTX has outperformed SLBT by 54.8 percentage points over the past year.

About Kyverna Therapeutics

KYTX stock →

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 172 employees

About SL Science

SLBT stock →

SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL bio's milk-derived exosome essence, SL bio's tangerine-derived extract, and the MilkExo concentrate series.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees

KYTX vs SLBT FAQ

Which is bigger, Kyverna Therapeutics or SL Science?

SL Science (SLBT) is larger, with a market capitalization of $308.42M compared with $269.33M for Kyverna Therapeutics (KYTX).

Which stock has performed better over the past year, KYTX or SLBT?

KYTX returned -39.92% over the past 12 months, compared with -94.76% for SLBT (price return, excluding dividends). Past performance does not predict future results.

Are Kyverna Therapeutics and SL Science in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons